-
Antimycin A4: Practical Metabolism Workflows
2026-09-20
Antimycin A4 combines ATP-citrate lyase inhibition with mitochondrial electron-transport blockade, making it a versatile but mechanistically demanding tool for lipid and energy-metabolism experiments. This guide presents a staged workflow, concentration design, assay controls, and troubleshooting strategies for obtaining interpretable results.
-
Selective ClpP Activation and Cell-Cycle Arrest in LUSC
2026-09-19
The reference study identifies ZK53 as a selective activator of human mitochondrial ClpP and shows that it suppresses lung squamous cell carcinoma through mitochondrial proteome disruption, impaired oxidative phosphorylation, and ATM-linked cell-cycle arrest. Its structural, cellular, and in vivo evidence connects mitochondrial proteostasis to DNA damage response signaling and provides a framework for target-based LUSC research.
-
ARCA Cy5 EGFP mRNA: Read the Delivery Path
2026-09-18
ARCA Cy5 EGFP mRNA (5-moUTP) enables researchers to separate cellular uptake from productive translation in mammalian mRNA delivery studies. This article presents a mechanism-first assay framework grounded in lipid nanoparticle research, with practical guidance for interpreting Cy5 and EGFP signals.
-
Angiotensin II: From Peptide to Injury Model
2026-09-18
Angiotensin II is more than a vasoconstrictor: it is a controllable tool for linking receptor signaling with vascular and renal injury. This guide translates a 2025 Ang II study into practical assay and model-selection decisions for cardiovascular research.
-
EZ Cap Cy5 Firefly Luciferase mRNA Workflows
2026-09-17
Pair fluorescent uptake data with luciferase output to distinguish delivery, intracellular trafficking, and productive translation in one assay. This dual-reporter workflow also adapts well to reverse-transfection and lyophilized lipoplex screening, helping researchers compare carrier formulations with fewer handling steps.
-
EZ Cap Cy5 Firefly Luciferase mRNA Guide
2026-09-17
A scenario-based guide to using EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP), SKU R1010, for mRNA delivery, transfection, viability, and cytotoxicity workflows. It explains how dual fluorescence and bioluminescence readouts, Cap1 capping, modified nucleotides, and disciplined handling improve interpretation without overstating product-specific evidence.
-
PR-619 Workflows for DUB Inhibition Research
2026-09-16
PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for separating DUB-driven ubiquitin accumulation from direct proteasome blockade. This practical guide covers dose-finding, autophagy imaging, cancer biology research, neurodegenerative disease models, and controls that reduce interpretation errors.
-
AO/PI Double Staining Kit: Practical Guide
2026-09-16
The AO/PI Double Staining Kit provides a rapid fluorescent cell staining workflow for separating viable, apoptotic, and necrotic populations using Acridine Orange and Propidium Iodide. It is suitable for research cell viability assays and preliminary apoptosis or necrosis detection, but it should not be treated as a standalone diagnostic or definitive pathway assay.
-
EZ Cap Cy5 Firefly Luciferase mRNA Workflow
2026-09-15
Track mRNA entry with Cy5 while measuring productive translation through firefly luciferase in the same experiment. This practical workflow connects delivery optimization, immune-aware assay design, and in vivo bioluminescence imaging without confusing cellular uptake with functional expression.
-
Maridomycin: In Vitro and In Vivo Activity
2026-09-15
The reference study established a broad antibacterial profile for maridomycin by combining susceptibility testing, resistance selection, bactericidal analysis, serum-binding measurements, and mouse infection experiments. Its findings show strong activity against many Gram-positive organisms, selective activity against some Gram-negative bacteria, macrolide-associated cross-resistance, and therapeutic effects in experimental infections.
-
Fulvestrant (ICI 182,780) Experimental Workflows
2026-09-14
Build reproducible ER-antagonism studies with Fulvestrant (ICI 182,780), from dose-response experiments in MCF7 and T47D cells to chemotherapy-sensitization and mechanistic validation. The workflow connects ERα depletion, MDM2 protein degradation, apoptosis, and carefully bounded immune-stress assays without overstating what cross-domain evidence can prove.
-
Gastric Cancer Assembloids Model Tumor–Stroma Complexity
2026-09-14
Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell subpopulations from the same tissue. The model reproduced clinically relevant tumor–stroma interactions, altered transcriptional programs, and patient- and drug-specific response patterns that were not apparent in tumor-only organoids.
-
BMS-777607: A Mechanistic Assay Guide
2026-09-13
BMS-777607 is a selective c-Met inhibitor for resolving MET-family signaling in cancer and stem-cell assays. This guide connects its biochemical profile with an optimized iPSC-derived platelet study while emphasizing controls, assay maturity, and interpretation limits.
-
Wallichinine Reverses ABCB1-Mediated MDR
2026-09-12
The 2016 study by Lv and colleagues identifies wallichinine as a natural-product inhibitor of ABCB1-mediated multidrug resistance, showing that it restores the activity of vincristine and doxorubicin in ABCB1-overexpressing cancer cells. Its combined cytotoxicity, drug-transport, ATPase, and modeling experiments provide a mechanistic framework for evaluating ABCB1 reversal agents while highlighting the limits of metabolic viability readouts alone.
-
Acetoacetic Acid Sodium Salt Workflows
2026-09-11
Build reproducible ketone-body experiments with a water-soluble sodium acetoacetate format, practical dosing guidance, and controls for diabetes and energy metabolism models. A deuterium-labeling study adds an analytical lesson: rigorous standardization and orthogonal verification can make metabolic measurements more defensible.